Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients

British Journal of Rheumatology

Volumn 36, Issue 12, 1997, Pages 1290-1297

  Gayraud, M ^a   Guillevin, L ^a   Cohen, P ^a   Lhote, F ^a   Cacoub, P ^a   Deblois, P ^a   Godeau, B ^a   Ruel, M ^a   Vidal, E ^a   Pointud, M ^a   Ducroix, J P ^a   Lassoued, S ^a   Christoforov, B ^a   Babinet, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Churg Strauss syndrome; Cyclophosphamide oral; Cyclophosphamide pulse; Polyarteritis nodosa

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; STEROID;

ACNE; ADULT; AGED; ALOPECIA; AMENORRHEA; ARTICLE; BONE NECROSIS; BRONCHITIS; CANDIDIASIS; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CUSHING SYNDROME; DRUG EFFICACY; FEMALE; FOLLICULITIS; FOLLOW UP; HEMORRHAGIC CYSTITIS; HEPATITIS; HERPES SIMPLEX KERATITIS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MALAISE; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PNEUMONIA; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SEX RATIO; SINUSITIS; STOMACH ULCER; URINARY TRACT INFECTION; WEIGHT GAIN;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYARTERITIS NODOSA; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0031468852     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Frohnert P, Sheps S. Long-term follow-up study of polyarteritis nodosa. Am J Med 1967;48:8-14.
2. Leib E, Restivo C, Paulus H. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979;67:941-7.
3. Fauci A, Katz P, Haynes B, Wolft S. Cyclophosphamide therapy of severe necrotizing vasculitis. N Engl J Med 1979;301:235-8.
4. Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Méd Intern (Paris) 1992;143:405-13.
5. Guillevin L, Jarrousse B, Lok C et al. Long-term follow-up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567-74.
6. Guillevin L, Fain O, Lhote F et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 1992;35:208-15.
7. Guillevin L, Lhote F, Léon A, Fauvelle F, Vivitski L, Trépo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short-term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993;20:289-98.
8. Guillevin L, Lhote F, Cohen P, Jarrousse B, Généreau T, Léon A. Lack of superiority of corticosteroids plus pulse cyclophosphamide and plasma exchanges to corticosteroids plus pulse cyclophosphamide in the treatment of polyarteritis nodosa and Churg-Strauss syndrome with poor prognostic factors. A prospective, randomized trial in 62 patients.. Arthritis Rheum 1992;35:208-15.
9. Guillevin L, Lhote F, Cohen P et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation in 41 patients. Medicine 1995;74:238-53.
10. Guillevin L, Lhote F, Sauvaget F et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994;53:334-7.
11. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996;75:17-28.
12. Lightfoot RJ, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-93.
13. Masi A, Hunder G, Lie J et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis angiitis). Arthritis Rheum 1990;33:1094-100.
14. Cooperating Clinics Committee of the American Rheumatism Association (ARA). A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 1970;283:883-9.
15. Fosdick W, Parsons J, Hill D. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968;11:151-61.
16. Stillwell TJ, Benson RJ, De Remee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988;31:465-70.
17. Stillwell T, Benson RJ, De Remee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients. Cancer 1988;61:451-7.
18. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989;32:45-53.
19. Godeau B, Coutant PV, Lê THD et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994;21: 246-51.
20. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
21. Jarrousse B, Guillevin L, Bindi E et al. Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis. Clin Exp Rheumatol 1993;11:615-21.
22. Sea RP, Walsh TP, Fisher W, Brock N. Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest 1991;99:143-6.
23. Austin H, Klippel J, Balow J et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
24. Luqmani R, Watts R, Scott D, Bacon P. Treatment of vasculitis in rheumatoid arthritis. Ann Méd Intern (Paris) 1994;145:566-76.
25. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403-10.
26. Haga HJ, D'Cruz D, Asherson R, Hughes GR. Short-term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992;51:885-8.
27. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone treatment in systemic rheumatoid vasculitis. Am J Med 1984;76:377-84.
28. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990;113:656-63.
29. Cupps T. Cyclophosphamide: to pulse or not to pulse? Am J Med 1990;89:399-402.
30. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse or oral cyclophosphamide in Wegener's granulomatosis: a study on 50 patients. Arthritis Rheum 1997; in press.